Pharmaceutical Technology

APRIL 13, 2023

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Production 279

Production Vaccine Vaccination Protein 279

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. We are confident it will be the milestone to solidify our position in the global market amid the transition of the pandemic to the endemic phase.”

Vaccine 298

Vaccine Vaccination Protein Medicine 298

XTalks

MARCH 26, 2025

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. Furthermore, the company reported a Q4 profit of $211 million on $3.95

Packaging 105

Packaging Packaging Protein Production 105

XTalks

NOVEMBER 29, 2023

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105

Protein Production Marketing Development 105

XTalks

JULY 26, 2023

Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.

Protein 97

Protein Production Cosmetics Marketing 97

Pharmaceutical Technology

FEBRUARY 25, 2025

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF) pipeline, particularly its lead candidates, SION-719 and SION-451, which work by stabilising the nucleotidebinding domain 1 domain of the CF transmembrane conductance regulator (..)

Marketing 147

Marketing Protein Regulation 147

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 171

FDA Approval Drugs Protein Antibody 171

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. That’s a hell of an incentive.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

XTalks

OCTOBER 11, 2021

Hormel Foods Corporation’s 199 Ventures which is the company’s venturing company, is entering the plant-based protein sphere by partnering with The Better Meat Co. Together, they will bring new mycoprotein and plant-based protein products to the market. The Better Meat Co. “We are excited to work with The Better Meat Co.

Production 105

Production Marketing Protein Branding 105

Pharmaceutical Technology

MARCH 12, 2024

The US company is part of a burgeoning artificial intelligence (AI) market in early-stage drug development.

Protein 130

Protein Marketing Development Drugs 130

Pharmaceutical Technology

JANUARY 20, 2023

BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

Marketing 130

Marketing Bioavailability Trials Clinical Trials 130

XTalks

FEBRUARY 7, 2025

In the biotechnology sector, a biotech IPO occurs when a biotech firm lists its shares on a stock exchange, thereby attracting investment from public markets. The companys approach combines small molecule therapies and targeted protein degradation.

Marketing 66

Marketing Genetics Vaccination Vaccine 66

Pharmaceutical Technology

SEPTEMBER 7, 2022

The diabetic macular oedema (DME) market is anticipated to reach values of $11.1bn in 2031 across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).

Marketing 130

Marketing Branding Protein Drugs 130

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Pharmaceutical Technology

DECEMBER 8, 2022

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

DECEMBER 15, 2022

The congenital fibrinogen deficiency (CFD) market is expected to grow at a compound annual growth rate (CAGR) of 1.7% through 2031, reaching over $800m across the three major markets (3MM: US, Germany, and Japan), according to GlobalData’s recent report: Congenital Fibrinogen Deficiency: Opportunity Assessment and Forecast.

Marketing 130

Marketing Production Genotype Development 130

Pharmaceutical Technology

AUGUST 17, 2022

In the last 20 years, this is the biggest buzz in the vaccine market for Lyme disease,” said Yale School of Medicine associate professor Sukanya Narasimhan, PhD, about the Phase III VLA15 trial. Sanofi had previously developed its own vaccine ImuLyme , which even completed Phase III evaluation, but it did not enter the market.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

Pharmaceutical Technology

JULY 18, 2022

CFTR modulators work by binding to the defective CFTR protein, improving its function, and in turn reducing the build-up of thick mucus. The post Addressing the treatment gap in the bronchiectasis market appeared first on Pharmaceutical Technology.

Marketing 147

Marketing Trials Development Protein 147

Pharmaceutical Technology

MARCH 16, 2023

These antibodies will be provided to pharma companies for conducting late-stage development and marketing. Immunoprecise Antibodies CEO and president Dr Jennifer Bath said: “As we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the ‘Holy Grail’ in oncology.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

JANUARY 16, 2024

Disco has built a protein mapping platform for cancer cell surfaces, to unlock targets for the antibody-based therapy market.

Protein 130

Protein Antibody Marketing 130

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Genetics 328

Genetics Medicine Development Gene Therapy 328

XTalks

AUGUST 25, 2022

BetterBrand, the startup behind the low-carb, high-protein Better Bagel , announced its global partnership with Whole Foods Market. One year after its online debut, BetterBrand’s Better Bagel hit the frozen shelves of over 500 Whole Foods Market locations, bringing its “Grain-Changing” technology to retail. . Million in Funding.

Marketing 92

Marketing Protein Production Branding 92

XTalks

SEPTEMBER 7, 2023

The Dutch brand, founded by Harmen Treep in 2008, recognized the immense gap in the market and created a line of lactase enzyme supplements tailored to cater to the lactose-intolerant community. The standout feature of Intoleran is its user-friendly lactase drops.

Production 105

Production Marketing Branding Protein 105

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

XTalks

JULY 20, 2021

Therefore, it’s only natural for companies to cater to this growing consumer market. There is exponential growth in the pet treat market and it is predicted to reach $72.6 In 2020, the pet treats global market made an estimated $21.4 In 2020, there were 27 pet food industry mergers and acquisitions.

Marketing 105

Marketing Branding Filler Packaging 105

Pharmaceutical Technology

JULY 29, 2022

An antibody cytokine fusion protein, N-803 is a new interleukin-15 (IL-15) superagonist complex. In January, ImmunityBio and Amyris have concluded a joint venture (JV) agreement announced previously to accelerate the marketing of a Covid-19 vaccine.

Trials 264

Trials Clinical Trials Clinical Trials Licensing 264

Pharmaceutical Technology

SEPTEMBER 2, 2022

Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. A group of ailments, haemoglobinopathies is associated with an irregular production or structure of the haemoglobin protein in the red blood cells.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Trials 264

Pharmaceutical Technology

JUNE 15, 2023

The market responded warmly to the reanalysis. Shares in Eloxx were up 19% at market open compared to previous day’s (14 June) close. ELX-02 is a small molecule drug designed to increase the probability full-length proteins are produced by promoting ribosomal function.

Trials 246

Trials Genetics Protein Marketing 246

Pharmaceutical Technology

NOVEMBER 14, 2022

binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. In February, the company signed a licencing agreement under which Eli Lilly and Company obtained exclusive rights to conduct the research, development and marketing of ADCs. The ADC comprises an FR?-binding

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

JULY 12, 2022

A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain. It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.

Vaccine 162

Vaccine Vaccination Protein Pharmacy 162

Pharmaceutical Technology

MARCH 11, 2024

Market-leading HCP analysis, as well as other process-related impurity analysis, is becoming smoother

Protein 100

Protein Production Marketing 100

BioPharma Reporter

AUGUST 21, 2022

EMA has begun its review of the conditional marketing authorization application from South Korean developer, SK biosciences, for its COVID-19 vaccine, Skycovion, a recombinant protein-based vaccine with adjuvant from GSK.

Vaccination 105

Vaccination Vaccine Protein Marketing 105

XTalks

NOVEMBER 6, 2024

per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. With an expanding patent portfolio and partnerships in human and animal health, Gelteq promotes therapeutic efficacy and patient adherence across diverse health markets.

Drug Delivery 104

Drug Delivery Drugs Bioequivalency Bioavailability 104

BioPharma Reporter

DECEMBER 20, 2021

The European Commission has granted conditional marketing authorisation to Novavax for its COVID-19 vaccine: making it the first protein-based COVID-19 vaccine in the EU.

Vaccine 98

Vaccine Vaccination Protein Marketing 98

Pharmaceutical Technology

SEPTEMBER 14, 2022

The protein-based vaccine is indicated as a two-dose initial regimen for active immunisation for the prevention of Covid-19 in adults aged 18 years and above. It is marketed under the brand name Covovax in the country. Currently, the vaccine has obtained authorisation in more than 43 countries for use in adults aged 18 and above.

Vaccine 147

Vaccine Vaccination Clinical Trials Clinical Trials 147